CYP19A1 and breast carcinoma: In our previous report, we suggest that increased expression of HSD3B1 might reduce sensitivity to aromatase inhibitors (AIs) in human breast cancer cell lines, as demonstrated by enhanced 3β‐diol‐induced ER activation and growth mechanisms 25.